Echo secures $3.6 million for wireless glucose monitor; OctoPlus to aid development of injectable joint treatment;

> Dutch specialty pharmaceutical company OctoPlus says it will begin working with a "leading U.S.-based pharmaceutical company" on a controlled release formulation of a joint treatment using its injectable PolyActive drug delivery technology. Release

> Echo Therapeutics ($ECTE) has raised $3.6 million in cash to help fuel final development of its non-invasive, wireless, transdermal continuous glucose monitoring system for diabetics and critical care patients. Release

> Percutaneous coronary intervention using newer drug-eluting stents to treat blocked arteries has lower rates of relapse, stent thrombosis and death than older drug-eluting and bare-metal stents, an analysis of more than 94,000 consecutive stent implantations in Sweden has found. Release

> U.K. RNAi company Silence Therapeutics will explore combining its DBTC delivery system with miRagen's novel microRNA-based therapeutics. DBTC is a lipid-based formulation that efficiently delivers siRNA to various types of liver cells. Release

> Unigene Laboratories has been granted a U.S. patent for appetite suppression and obesity treatments that use its peptide drug-delivery technology. Release

> Israel's Oramed Pharmaceuticals has filed a patent application to develop an oral formulation combining two diabetes drugs currently available only in injectable form. Release

> Arcion Therapeutics has received a notice of allowance for a U.S. patent for its high strength, water-based gel formulation of topical lidocaine to treat post-herpetic neuralgia and shingles. Release